BigThink Signs Exclusive Distribution and Sales Agreement for 'Longquix Prefilled Syringe' with Handok Teva

BigThink Therapeutics, a bio-subsidiary of KPS, announced on the 24th that it has signed an exclusive sales agreement for Handok Teva's long-acting neutropenia treatment, Longquix Prefilled Injection (active ingredient: Lipegfilgrastim). BigThink will begin distribution and sales of Longquix Prefilled Injection starting today.

Last year, BigThink also formed a strategic partnership with Boryung and has been jointly conducting sales and marketing for the breast cancer drug Nerings Tablet (active ingredient: Neratinib Maleate). With this new contract, the expansion of its anticancer drug pipeline is expected to further solidify its position as a specialized anticancer pharmaceutical company.

According to BigThink, Longquix Prefilled Injection is a treatment that reduces the duration of severe neutropenia occurring during cancer therapy. It is equipped with a safety needle guard to improve patient convenience and, notably, is the only drug in Korea approved for pediatric and adolescent patients aged 2 years and older.

Through this strategic partnership, BigThink plans to expand its anticancer drug portfolio beyond the breast cancer market, where it has already established a foothold.

In addition to Longquix Prefilled Injection, BigThink's anticancer pipeline includes the breast cancer treatment Nerings Tablet, Boryung's Pulvet Injection (active ingredient: Fulvestrant), and Mucosamin, which is effective in preventing and treating oral mucositis in cancer patients. Notably, Nerings Tablet, introduced by BigThink in 2022, recorded solid sales, surpassing 10 billion KRW in cumulative sales last year.

The company plans to complete a new immuno-oncology drug contract currently under negotiation within this year to strengthen its lineup of anticancer drugs with diverse technologies.

Kim Hayong, CEO of BigThink, stated, “Mucosamin, for which we hold Asian distribution rights, is scheduled for approval and sales this year in Taiwan, Thailand, Malaysia, and other countries. We are confident that this year will be the first year to surpass 10 billion KRW in sales through product line expansion and strengthened domestic and international sales activities.”